靶向警报素单克隆抗体治疗哮喘的研究进展  

Research Progress in Monoclonal Antibodies Targeting Alarmins in Treatment of Asthma

作　　者：段佳琦 程保辉 赵海亮 DUAN Jiaqi;CHENG Baohui;ZHAO Hailiang(Zhuhai Campus of Zunyi Medical University,Zhuhai 519041,China;Department of Otolaryngology,Shenzhen Longgang Otolaryngology Hospital/Shenzhen Otolaryngology Institute,Shenzhen 518172,China)

机构地区：[1]遵义医科大学珠海校区,广东珠海519041 [2]深圳市龙岗区耳鼻咽喉医院耳鼻咽喉科深圳市耳鼻咽喉研究所,广东深圳518172

出　　处：《医学综述》2023年第8期1467-1474,共8页Medical Recapitulate

基　　金：国家自然科学基金(81973915);深圳市医学重点学科建设项目(SZXK039)。

摘　　要：哮喘是一种以慢性气道炎症为主要特征的异质性疾病。变应原、空气污染物等触发呼吸道上皮细胞产生的警报素——胸腺基质淋巴生成素、白细胞介素(IL)-33和IL-25在哮喘发病中发挥重要作用。警报素可直接激活2型固有淋巴细胞、嗜酸粒细胞、嗜碱粒细胞和肥大细胞,也可刺激树突状细胞驱动辅助性T细胞(Th细胞)0向Th2细胞表型转化,参与2型哮喘的发生发展。目前靶向警报素单克隆抗体治疗哮喘的研究已进入临床试验阶段。未来人源性抗警报素单克隆抗体或可成为哮喘治疗的有效方案,为疾病的治疗提供新思路。Asthma is a heterogeneous disease characterized by chronic airway inflammation.Allergens,air pollutants,etc.trigger the epithelial-derived alarmins including thymic stromal lymphopoietin,interleukin(IL)-33 and IL-25 production,which play important roles in the pathogenesis of asthma.The alarmins can directly activate group 2 innate lymphoid cells,eosinophils,basophils and mast cells,and also stimulate dendritic cells to drive the commitment of helper T cell(Th cell)towards the Th2 cell immunophenotype,resulting in type 2 asthma eventually.At present,the research on the treatment of asthma with monoclonal antibodies targeting alarmin has entered the clinical trial stage.In the future,human anti-alarmin monoclonal antibodies may become an effective option for asthma treatment and provide new ideas for the treatment of the disease.

关 键 词：哮喘 胸腺基质淋巴生成素 白细胞介素-33 白细胞介素-25 警报素 

分 类 号：R562.2[医药卫生—呼吸系统]